{"entity":{"id":"ab-3028","kind":"drug","name":"AB-3028","aka":[],"tldr":"AB-3028 is an experimental autologous programmable circuit T cell therapy from Arsenal Biosciences, in phase 1 trials for metastatic castration-resistant prostate cancer.","summary":"AB-3028 is an autologous programmable circuit T cell therapy from Arsenal Biosciences. An autologous T cell therapy (the registry calls it a programmable circuit T cell therapy) for metastatic castration-resistant prostate cancer; patients must be PSMA-positive on PSMA PET, but no source reached states its targets. Its furthest stage is phase 1, for metastatic castration-resistant prostate cancer. ClinicalTrials.gov registers it in one study linked below. Phase 1/2 NCT07285694 active, not recruiting; started 9 January 2026. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Arsenal Biosciences: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT07285694"},{"label":"ClinicalTrials.gov: trials of AB-3028","url":"https://clinicaltrials.gov/search?intr=AB-3028"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate-mcrpc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["arsenal-bio"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07285694"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"AB-3028","modality":"Autologous programmable circuit T cell therapy","mechanism":"An autologous T cell therapy (the registry calls it a programmable circuit T cell therapy) for metastatic castration-resistant prostate cancer; patients must be PSMA-positive on PSMA PET, but no source reached states its targets.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/ab-3028/","neighbours":{"cancer":[{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"}],"company":[{"id":"arsenal-bio","kind":"company","name":"Arsenal Biosciences","route":"/companies/arsenal-bio/"}],"trial":[{"id":"nct07285694","kind":"trial","name":"AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)","route":"/trials/nct07285694/"}]}}